Breaking New Ground in Targeting Dysfunctional Metabolic Pathways in the Liver: Inhibition of FASN in NASH Patients with the First-in-Class Drug, Denifanstat

Time: 3:30 pm
day: Day Two


  • Evaluating the ability of FASN inhibition to improve the key drivers of NASH by: reducing liver fat, inflammation, and fibrosis
  • Validating digital imaging and non-invasive diagnostics as biomarkers of liver injury and predictors of response in clinical trials
  • Exploring initial clinical data in FASCINATE-2, a Phase IIb denifanstat study